Ken Griffin Kamada LTD Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kamada LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 200 shares of KMDA stock, worth $1,210. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200

Previous 2,200 90.91%

Holding current value

$1,210

Previous $10,000 90.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.83 - $6.25 $76,434 - $98,906	15,825 Added 52.22%	46,129 $247,000
Q2 2024 Aug 14, 2024	BUY	$4.78 - $5.75 $7,404 - $8,906	1,549 Added 5.39%	30,304 $150,000
Q1 2024 May 15, 2024	BUY	$5.58 - $6.42 $27,425 - $31,554	4,915 Added 20.62%	28,755 $161,000
Q4 2023 Feb 14, 2024	SELL	$4.14 - $6.22 $5,684 - $8,540	-1,373 Reduced 5.45%	23,840 $145,000
Q3 2023 Nov 14, 2023	BUY	$4.86 - $5.83 $3,790 - $4,547	780 Added 3.19%	25,213 $134,000
Q2 2023 Aug 14, 2023	SELL	$4.48 - $5.53 $27,713 - $34,208	-6,186 Reduced 20.2%	24,433 $129,000
Q1 2023 May 15, 2023	BUY	$4.12 - $5.25 $21,728 - $27,688	5,274 Added 20.81%	30,619 $142,000
Q4 2022 Feb 14, 2023	BUY	$3.79 - $4.84 $96,057 - $122,669	25,345 New	25,345 $101,000
Q3 2021 Nov 15, 2021	SELL	$5.25 - $5.87 $29,027 - $32,455	-5,529 Reduced 30.73%	12,465 $66,000
Q2 2021 Aug 16, 2021	BUY	$5.67 - $6.33 $23,933 - $26,718	4,221 Added 30.65%	17,994 $104,000
Q1 2021 May 17, 2021	BUY	$6.02 - $8.06 $82,913 - $111,010	13,773 New	13,773 $85,000
Q1 2018 May 11, 2018	SELL	$4.6 - $5.75 $60,646 - $75,808	-13,184 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$4.35 - $5.15 $57,350 - $67,897	13,184	13,184 $63,000

Others Institutions Holding KMDA

# of Institutions

Shares Held

6.48M

Call Options Held

200

Put Options Held

View Full List

About KAMADA LTD

Ticker KMDA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 44,800,500
Market Cap $271M
Description
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...

More about KMDA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account